FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295298209> ?p ?o ?g. }

• W4295298209 endingPage "S244" @default.
• W4295298209 startingPage "S244" @default.
• W4295298209 abstract "Objectives: The objectives of this epidemiologic study were to investigate potential misdiagnosis of synchronous endometrial and ovarian cancers, utilizing the Surveillance Epidemiology and End Results (SEER) Program, which is a population-based tumor registry. We hypothesize that women diagnosed with synchronous tumors may have worse overall survival than those with nonsynchronous stage I tumors, closer to stage IIIA endometrial cancer due to misdiagnosis and potential undertreatment. Methods: This retrospective observational study utilized the SEER database to compare synchronous uterine and ovarian cancers cases to those of separate, primary endometrial and ovarian cancers. Kaplan-Meier analyses were used to construct overall survival curves, which were compared with log-rank tests. Cox proportional hazard regression models were utilized to adjust for age, adjuvant treatments, and histologic and grade subgroup pairings. Magnitudes of statistical significance were expressed with age-adjusted HR and 95% CI. Results: Women with stage I synchronous tumors had the highest progression-free survival of all groups compared to stage I non-syn- chronous (NS) ovarian and uterine cancers and NS stage IIIA uterine cancers with an HR of 0.44. The mean age at diagnosis for synchronous cancers was 52.54 years, compared to 61.53 for all other groups. After adjusting for age, the synchronous cancers continue to have the highest survival with a statistically significant HR of 0.74 (p=0.005). The most common histology type for synchronous cancers was endometrioid for both uterine and ovarian (n=593), with endometrioid uterine and serous ovarian histology types being the second most common (n=42). In a subgroup analysis with grade I endometrioid carcinomas of the uterus and ovary versus primary grade I endometrioid NS stage I of the ovary and NS stage I of the uterus, the improved survival relationship remains for the synchronous cancers (HR: 0.86, 0.60). In a similar subgroup limited to those patients with known chemotherapy or radiation treatment, those with synchronous cancers continue to have improved survival comparatively (HR: 0.54, 0.55). Conclusions: Contrary to our hypothesis, those diagnosed with synchronous cancers had improved survival than NS stage I primary uterine or ovarian cancers and stage IIIA uterine cancers. The survival advantage of patients with synchronous tumors is attributed to factors, including younger age, endometrioid histology, lower grade, and receipt of adjuvant treatment; however, after adjusting for these variables, the survival benefit relationship continued. Further studies need to be done for improved understanding, including HRD and molecular testing, which we are currently investigating. Objectives: The objectives of this epidemiologic study were to investigate potential misdiagnosis of synchronous endometrial and ovarian cancers, utilizing the Surveillance Epidemiology and End Results (SEER) Program, which is a population-based tumor registry. We hypothesize that women diagnosed with synchronous tumors may have worse overall survival than those with nonsynchronous stage I tumors, closer to stage IIIA endometrial cancer due to misdiagnosis and potential undertreatment. Methods: This retrospective observational study utilized the SEER database to compare synchronous uterine and ovarian cancers cases to those of separate, primary endometrial and ovarian cancers. Kaplan-Meier analyses were used to construct overall survival curves, which were compared with log-rank tests. Cox proportional hazard regression models were utilized to adjust for age, adjuvant treatments, and histologic and grade subgroup pairings. Magnitudes of statistical significance were expressed with age-adjusted HR and 95% CI. Results: Women with stage I synchronous tumors had the highest progression-free survival of all groups compared to stage I non-syn- chronous (NS) ovarian and uterine cancers and NS stage IIIA uterine cancers with an HR of 0.44. The mean age at diagnosis for synchronous cancers was 52.54 years, compared to 61.53 for all other groups. After adjusting for age, the synchronous cancers continue to have the highest survival with a statistically significant HR of 0.74 (p=0.005). The most common histology type for synchronous cancers was endometrioid for both uterine and ovarian (n=593), with endometrioid uterine and serous ovarian histology types being the second most common (n=42). In a subgroup analysis with grade I endometrioid carcinomas of the uterus and ovary versus primary grade I endometrioid NS stage I of the ovary and NS stage I of the uterus, the improved survival relationship remains for the synchronous cancers (HR: 0.86, 0.60). In a similar subgroup limited to those patients with known chemotherapy or radiation treatment, those with synchronous cancers continue to have improved survival comparatively (HR: 0.54, 0.55). Conclusions: Contrary to our hypothesis, those diagnosed with synchronous cancers had improved survival than NS stage I primary uterine or ovarian cancers and stage IIIA uterine cancers. The survival advantage of patients with synchronous tumors is attributed to factors, including younger age, endometrioid histology, lower grade, and receipt of adjuvant treatment; however, after adjusting for these variables, the survival benefit relationship continued. Further studies need to be done for improved understanding, including HRD and molecular testing, which we are currently investigating." @default.
• W4295298209 created "2022-09-12" @default.
• W4295298209 creator A5012509205 @default.
• W4295298209 creator A5050104828 @default.
• W4295298209 creator A5059944529 @default.
• W4295298209 creator A5066858103 @default.
• W4295298209 creator A5070503342 @default.
• W4295298209 creator A5075544315 @default.
• W4295298209 date "2022-08-01" @default.
• W4295298209 modified "2023-09-26" @default.
• W4295298209 title "Misdiagnosed and over- or undertreated? Patients with synchronous ovarian and uterine cancers outperform those with single primaries (493)" @default.
• W4295298209 doi "https://doi.org/10.1016/s0090-8258(22)01715-2" @default.
• W4295298209 hasPublicationYear "2022" @default.
• W4295298209 type Work @default.
• W4295298209 citedByCount "0" @default.
• W4295298209 crossrefType "journal-article" @default.
• W4295298209 hasAuthorship W4295298209A5012509205 @default.
• W4295298209 hasAuthorship W4295298209A5050104828 @default.
• W4295298209 hasAuthorship W4295298209A5059944529 @default.
• W4295298209 hasAuthorship W4295298209A5066858103 @default.
• W4295298209 hasAuthorship W4295298209A5070503342 @default.
• W4295298209 hasAuthorship W4295298209A5075544315 @default.
• W4295298209 hasConcept C107130276 @default.
• W4295298209 hasConcept C121608353 @default.
• W4295298209 hasConcept C126322002 @default.
• W4295298209 hasConcept C143998085 @default.
• W4295298209 hasConcept C146357865 @default.
• W4295298209 hasConcept C150173356 @default.
• W4295298209 hasConcept C151730666 @default.
• W4295298209 hasConcept C207103383 @default.
• W4295298209 hasConcept C2777088508 @default.
• W4295298209 hasConcept C2778527826 @default.
• W4295298209 hasConcept C2779391198 @default.
• W4295298209 hasConcept C2780427987 @default.
• W4295298209 hasConcept C29456083 @default.
• W4295298209 hasConcept C44249647 @default.
• W4295298209 hasConcept C50382708 @default.
• W4295298209 hasConcept C71924100 @default.
• W4295298209 hasConcept C86803240 @default.
• W4295298209 hasConceptScore W4295298209C107130276 @default.
• W4295298209 hasConceptScore W4295298209C121608353 @default.
• W4295298209 hasConceptScore W4295298209C126322002 @default.
• W4295298209 hasConceptScore W4295298209C143998085 @default.
• W4295298209 hasConceptScore W4295298209C146357865 @default.
• W4295298209 hasConceptScore W4295298209C150173356 @default.
• W4295298209 hasConceptScore W4295298209C151730666 @default.
• W4295298209 hasConceptScore W4295298209C207103383 @default.
• W4295298209 hasConceptScore W4295298209C2777088508 @default.
• W4295298209 hasConceptScore W4295298209C2778527826 @default.
• W4295298209 hasConceptScore W4295298209C2779391198 @default.
• W4295298209 hasConceptScore W4295298209C2780427987 @default.
• W4295298209 hasConceptScore W4295298209C29456083 @default.
• W4295298209 hasConceptScore W4295298209C44249647 @default.
• W4295298209 hasConceptScore W4295298209C50382708 @default.
• W4295298209 hasConceptScore W4295298209C71924100 @default.
• W4295298209 hasConceptScore W4295298209C86803240 @default.
• W4295298209 hasLocation W42952982091 @default.
• W4295298209 hasOpenAccess W4295298209 @default.
• W4295298209 hasPrimaryLocation W42952982091 @default.
• W4295298209 hasRelatedWork W2054579795 @default.
• W4295298209 hasRelatedWork W2117571685 @default.
• W4295298209 hasRelatedWork W2307349321 @default.
• W4295298209 hasRelatedWork W2329679828 @default.
• W4295298209 hasRelatedWork W2572837865 @default.
• W4295298209 hasRelatedWork W2584662937 @default.
• W4295298209 hasRelatedWork W2589944840 @default.
• W4295298209 hasRelatedWork W2748373020 @default.
• W4295298209 hasRelatedWork W3037269251 @default.
• W4295298209 hasRelatedWork W3153407610 @default.
• W4295298209 hasVolume "166" @default.
• W4295298209 isParatext "false" @default.
• W4295298209 isRetracted "false" @default.
• W4295298209 workType "article" @default.